Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Tian Zhang, MD, explains how to treat mRCC after combination I-O in the 1st line setting

Dr. Zhang, Assistant Professor of Medicine, Duke Cancer Institute, explains how to treat metastatic renal cell carcinoma (mRCC) after combination I-O in the 1st line setting

Published: 22 February 2019

Recent Videos: Kidney (Renal Cell) Cancer

video

Tian Zhang, MD, explains how to treat mRCC after combination I-O in the 1st line setting

Dr. Zhang, Assistant Professor of Medicine, Duke Cancer Institute, explains how to treat metastatic renal cell carcinoma (mRCC) after combination ...

video

Michael Atkins, MD, considers how to treat mRCC after combination I-O in the 1st line setting

Dr. Atkins, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical Center, ...

video

Tian Zhang, MD, discusses intermediate/poor and favorable risk RCC patients

Dr. Zhang, Assistant Professor of Medicine, Duke Cancer Institute, explains how we may treat intermediate/poor risk renal cell cancer ...

video

Michael Atkins, MD, considers intermediate/poor & favorable risk RCC patients

Dr. Atkins, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical Center, ...

video

Tian Zhang, MD, elaborates on the outcomes of KEYNOTE 426 presented at GU 2019

Dr. Zhang, Assistant Professor of Medicine, Duke Cancer Institute, shares outcomes from the KEYNOTE 426 Phase III study investigating ...

video

Tian Zhang, MD, on predictive biomarkers in selecting patient populations for I-O treatment in RCC

Dr. Zhang, Assistant Professor of Medicine, Duke Cancer Institute, discusses relevant predictors of outcomes for immunotherapy treatment in metastatic renal ...

video

Rana McKay, MD, explains how to differentiate between TKIs available for renal cell cancer patients

Dr. McKay, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, describes how to differentiate between the various ...

video

Rana McKay, MD, on next steps when treating mRCC patients who receive I-O in the front line space

Dr. McKay, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, considers how to treat patients with metastatic ...

video

Rana McKay, MD, offers impressions of the TIVO-3 study in highly refractory advanced RCC patients

Dr. McKay, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, shares thoughts on the outcomes from the ...

video

Rana McKay, MD, on recent data examining atezolizumab and bevacizumab in nccRCC & sccRCC

Dr. McKay, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, offers opinion on whether the results of ...

Related Videos

video-image

Michael Atkins, MD, considers how to treat mRCC after combination I-O in the 1st line setting

video-image

Tian Zhang, MD, discusses intermediate/poor and favorable risk RCC patients

video-image

Michael Atkins, MD, considers intermediate/poor & favorable risk RCC patients

video-image

Tian Zhang, MD, elaborates on the outcomes of KEYNOTE 426 presented at GU 2019

video-image

Tian Zhang, MD, on predictive biomarkers in selecting patient populations for I-O treatment in RCC

video-image

Rana McKay, MD, explains how to differentiate between TKIs available for renal cell cancer patients

video-image

Rana McKay, MD, on next steps when treating mRCC patients who receive I-O in the front line space

video-image

Rana McKay, MD, offers impressions of the TIVO-3 study in highly refractory advanced RCC patients

video-image

Rana McKay, MD, on recent data examining atezolizumab and bevacizumab in nccRCC & sccRCC

video-image

Rana McKay, MD, considers the implications of CHECKMATE 214 & KEYNOTE-426 presented at GU 2019

video-image

Rana McKay, MD, elaborates on the outcomes of the KEYNOTE 426 Phase III study in mRCC

video-image

Michael Atkins, MD, offers opinion on IO-TKI combinations in renal cell cancer

video-image

Michael Atkins, MD, regarding the KEYNOTE 426 Phase III trial in metastatic renal cell carcinoma

video-image

Richard Finn, MD, outlines the role of TACE with systemic therapy in HCC

video-image

Richard Finn, MD, considers the effectiveness of sorafenib + I-O in newly diagnosed HCC

video-image

Raymond Wadlow, MD, on surrogate biomarkers in the treatment of hepatocellular carcinoma

video-image

Richard Finn, MD, elaborates on current treatment options & sequencing of TKIs in HCC

video-image

Zev Wainberg, MD, regarding the results of the ROAR basket trial from GI 2019

video-image

Raymond Wadlow, MD, speculates on the use of TKIs in the management of HCC

video-image

Zev Wainberg, MD, considers regorafenib in locally advanced biliary tract cancer

video-image

Richard Finn, MD, speculates on combined checkpoint inhibition in HCC & biliary tract cancer

video-image

Richard Finn, MD, shares his thoughts on the role of systemic therapy in HCC

video-image

Rachna Shroff, MD, on the utilization of TKIs in treatment of hepatocellular carcinoma

video-image

Richard Kim, MD, shares how we can utilize TKIs in the management of hepatocellular carcinoma

video-image

Andrew X. Zhu, MD, PhD, considers whether sorafenib is tolerable in combination with I-O in HCC

video-image

Andrew X. Zhu, MD, PhD, on what physicians should know about sequencing TKIs in HCC

video-image

Andrew X. Zhu, MD, PhD, regarding checkpoint inhibitors in advanced HCC

video-image

Alan Venook, MD, shares key takeaways from GI 2019 regarding the treatment of biliary tract cancers

video-image

Alan Venook, MD, on the latest in identifying valid biomarkers in the treatment of HCC

video-image

Nevena Damjanov, MD, regarding the impact of the ReDOS study in HCC

video-image

Nevena Damjanov, MD, elaborates on stereotactic body radiation therapy in early stage HCC

video-image

Nevena Damjanov, MD, regarding sequencing TKIs in hepatocellular carcinoma (HCC)

video-image

Nevena Damjanov, MD, shares thoughts on the role of systemic therapy in HCC

video-image

Robert A. Figlin, MD, on the convenience factor of oral TKIs & treatment decisions in advanced RCC

video-image

Robert A. Figlin, MD, on the trade-offs between safety & efficacy when discussing 1st line RCC

video-image

Robert A. Figlin, MD, provides perspective on I-O failures

video-image

Robert A. Figlin, MD, on deciding which metastatic RCC patients should get a TKI as 1st line therapy

video-image

Robert A. Figlin, MD, on how checkpoint inhibitors figure into treatment for 1st line RCC patients

video-image

Walter Stadler, MD, regarding TKIs in the treatment of renal cell carcinoma

video-image

Walter Stadler, MD, on treating RCC in the 2nd line setting following I-O failure

video-image

Walter Stadler, MD, considers which mRCC patients should receive a TKI as 1st line therapy

video-image

David I. Quinn, MD, provides perspective on the trade-offs between safety & efficacy in 1st line RCC

video-image

David I. Quinn, MD, considers whether the convenience of oral TKIs impacts RCC treatment

video-image

David I. Quinn, MD, comments on 2nd line therapy options following I-O failure

video-image

David I. Quinn, MD, shares thoughts on Keynote 427 from the 2018 ASCO Annual Meeting

video-image

David I. Quinn, MD, regarding the most exciting RCC data coming out of ASCO 2018

video-image

Jeanny B. Aragon-Ching, MD, FACP, shares how checkpoint inhibitors fit into RCC treatment algorithms

video-image

Jeanny B. Aragon-Ching, MD, FACP, comments on 2nd line treatment options in RCC after I-O failure

video-image

Ghassan Abou-Alfa, MD, MBA, regarding the shortcomings of the RECIST study in HCC

video-image

Ghassan Abou-Alfa, MD, MBA, shares the outcomes of the CELESTIAL study from ASCO 2018

video-image

Ghassan Abou-Alfa, MD, MBA, considers how immunotherapies should be combined with TKIs

video-image

Ghassan Abou-Alfa, MD, MBA, on the latest in systemic therapy for advanced HCC

video-image

Primo N. Lara, Jr., MD, comments on which TKIs appear most effective in 1st line RCC

video-image

Primo N. Lara, Jr., MD, on whether the convenience of oral TKIs influences treatment decisions

video-image

Primo N. Lara, Jr., MD, considers the trade-offs between safety & efficacy in 1st line RCC treatment

video-image

Primo N. Lara, Jr., MD, regarding the treatment path following I-O failure

video-image

Primo N. Lara, Jr., MD, on deciding which mRCC patients should receive a TKI

video-image

Primo N. Lara, Jr., MD, on how checkpoint inhibitors fit into RCC treatment algorithms

video-image

Brian I. Rini, MD, FACP, comments on the CARMENA study presented at ASCO 2018

video-image

Brian I. Rini, MD, FACP, discusses the influence of the convenience of oral TKIs

video-image

Brian I. Rini, MD, FACP, regarding the trade-offs between safety & efficacy in 1st line RCC

video-image

Brian I. Rini, MD, FACP, considers 2nd line treatment in advanced RCC following I-O failure

video-image

Brian I. Rini, MD, FACP, on which metastatic RCC patients should receive a TKI as 1st line therapy

video-image

Brian I. Rini, MD, FACP, on how checkpoint inhibitors figure into treatment algorithms for RCC

video-image

David I. Quinn, MD, on which metastatic RCC patients should receive a TKI as first-line therapy

video-image

Naomi B. Haas, MD, on how patient characteristics play a role in sequencing in metastatic RCC

video-image

Naomi B. Haas, MD, on how immunotherapies are being integrated into kidney cancer treatment

video-image

Naomi B. Haas, MD, explains how cabozantinib is being integrated into treatment of renal cell cancer

video-image

Naomi B. Haas, MD, offers opinion on the optimal sequencing of agents in treatment of RCC

video-image

Naomi B. Haas, MD, considers the role of TKIs in the treatment of renal cell cancer

video-image

Naomi B. Haas, MD, on what clinical evidence can tell us about the adjuvant treatment of RCC

video-image

Daniel J. George, MD, regarding toxicity concerns when using sunitinib in RCC

video-image

Daniel J. George, MD, on the effectiveness of sunitinib in the adjuvant treatment of high-risk RCC

video-image

Nevena Damjanov, MD, shares the latest news in systemic therapy for advanced HCC at ASCO 2018

video-image

Nevena Damjanov, MD, on the use of pembrolizumab in HCC patients previously treated with sorafenib

video-image

Nevena Damjanov, MD, outlines the role of TACE with systemic therapy in HCC patients

video-image

Richard Kim, MD, offers opinion on the ReDOS study and dose escalation of regorafenib

video-image

Nevena Damjanov, MD, discusses current treatment options and sequencing TKIs in HCC

video-image

Nevena Damjanov, MD, considers the shortcomings of RECIST in measuring efficacy in HCC patients

video-image

Richard Kim, MD, discusses pembrolizumab as an effective agent in HCC management

video-image

Richard Kim, MD, considers the effectiveness of combination sorafenib and TACE in HCC patients

video-image

Richard Kim, MD, on the use and sequencing of TKIs in hepatocellular carcinoma (HCC)

video-image

Andrew Zhu, MD, PhD, on the effectiveness of pembrolizumab in HCC patients treated with sorafenib

video-image

Andrew Zhu, MD, PhD, shares thoughts on treating adjuvant hepatocellular carcinoma (HCC) today

video-image

Laura Dawson, MD, FRCPC, discusses the design of the START study in HCC

video-image

Laura Dawson, MD, FRCPC, provides some background on hepatocellular carcinoma (HCC)

video-image

Andrew Zhu, MD, PhD, shares the latest in systemic therapy for advanced HCC at ASCO GI 2018

video-image

Andrew Zhu, MD, PhD, on how we diagnose and assess response in HCC patients

video-image

Jeffrey Meyerhardt, MD, offers opinion on the effectiveness of SIRT in treatment of metastatic HCC

video-image

Richard Goldberg, MD, FASCO, shares his impression of the adjuvant biliary tract study at ASCO 2017

video-image

Philip Philip, MD, on the lenvatinib data in patients with unresectable HCC presented at ASCO 2017

video-image

Philip Philip, MD, shares his impression of the capcitabine data in biliary cancers

video-image

Robert Figlin, MD, explains how checkpoint inhibitors are changing the way RCC is treated

video-image

Robert Figlin, MD, discusses sequencing when treating metastatic RCC patients

video-image

Robert Figlin, MD, on choosing the most appropriate treatment algorithm for metastatic RCC patients

video-image

Robert Figlin, MD, offers his opinion on interesting abstracts at ASCO 2017 related to RCC

video-image

Robert Figlin, MD, speculates on the changing landscape of RCC treatment

video-image

Nevena Damjanov, MD, comments on identifying subgroups of patients for targeted therapies in HCC

video-image

Nevena Damjanov, MD, on the Phase 3 Checkpoint 459 trial studying nivolumab in HCC

video-image

Nevena Damjanov, MD, shares her impressions of lenvatinib data in 1st line uHCC presented at ASCO

video-image

Nevena Damjanov, MD, discusses new agents being studied for treatment of advanced HCC

video-image

Ulka N. Vaishampayan, MD, on challenges facing patients and providers

video-image

Mohamad E. Allaf, MD, on immunotherapies and renal cell carcinoma treatment algorithms

video-image

Eric Jonasch, MD, on integrating immunotherapies into renal cell carcinoma treatment algorithms

video-image

Mohamad E. Allaf, MD, provides insight into treating metastatic non-clear cell renal cell carcinoma

video-image

Ulka N. Vaishampayan, MD, on immunotherapies and renal cell carcinoma treatment algorithms

video-image

Eric Jonasch, MD, on targeted therapies used to treat non-clear cell renal cell carcinoma

video-image

Eric Jonasch, MD, on approaches to consider with metastatic non-clear renal cell carcinoma

video-image

Aly-Khan Lalani, MD, offers feedback on using immunotherapies to treat renal cell carcinoma patients

video-image

Mohamad E. Allaf, MD, on helping non-metastatic renal cell carcinoma patients with adjuvant therapy

video-image

Ulka N. Vaishampayan, MD, on metastatic renal cell carcinoma patients and chemotherapy

video-image

Eric Jonasch, MD, on treating non-metastatic renal cell carcinoma patients with adjuvant therapy

video-image

Aly-Khan Lalani, MD, examines the integration of immunotherapies for renal cell carcinoma treatment

video-image

Mohamad E. Allaf, MD, on non-metastatic renal cell cancer patients and adjuvant therapy

video-image

Eric Jonasch, MD, on which non-metastatic renal cell cancer patients should receive adjuvant therapy

video-image

John L. Marshall, MD, talks about the results of the RESORCE trial

video-image

Alan P. Venook, MD, on identifying subgroups of HCC patients that are likely to respond to therapy

video-image

Alan P. Venook, MD, on if the RESORCE trial will change the role of regorafenib

video-image

Alan P. Venook, MD, on integrating immunotherapy into existing treatment regimens for HCC patients

video-image

Thomas A. Abrams, MD, on how checkpoint inhibitors will be incorporated into treatment of HCC

video-image

Thomas A. Abrams, MD, on reliably identifying subgroups of patients for targeted therapies in HCC

video-image

Thomas A. Abrams, MD, discusses the outcomes of the RESORCE trial as presented here at ASCO GI 2017

video-image

Thomas A. Abrams, MD, on how new agents being studied for HCC will be integrated into the treatment

video-image

Robert A. Figlin, MD on clinical study that lead to approval of lenvatinib (Lenvima)

video-image

Anthony El-Khoueiry, MD, talks results of nivolumab (Opdivo) trial in Hepatocellular Carcinoma (HCC)

video-image

Anthony El-Khoueiry, MD, discusses the pipeline of products in development for HCC

video-image

Anthony El-Khoueiry, MD, discusses management of Nexavar (Sorafenib) toxicities in HCC

video-image

Anthony El-Khoueiry, MD, discusses impact of new data on HCC Standard of care over last few years

video-image

Nevena Damianov, MD on the reasoning for studying PD-L1 inhibition in advanced HCC

video-image

Nevena Damianov, MD relays which late stage clinical studies will impact in advanced HCC

video-image

Nevena Damianov, MD interprets how new advanced HCC agents will integrate into HCC treatment

video-image

Robert Figlin, MD discusses how lenvatanib will fit into the advanced RCC treatment algorithm

video-image

Robert Figlin, MD, discusses recent progress in the treatment of renal cell cancer (RCC)

video-image

Robert Filgin MD explains the importance of cabozantinib as a tool in the RCC armamentarium

video-image

Robert Filgin MD provides an update on nivolumab (Opdivo) in RCC

video-image

Nevena Damianov, MD illustrates the promising classes and products for advanced, unresectable HCC

video-image

Nevena Damianov, MD discusses the toxicity concerns and how to manage them for sorafenib in HCC

video-image

Kidney Cancer Highlights from ASCO GU 2016 Genitourinary Symposium

video-image

Nicholas Vogelzang, MD, FASCO, FACP, regarding sipuleucel-T in mCRPC

video-image

Tian Zhang, MD, on whether patients in the 1st line setting should receive a single agent TKI

video-image

Nicholas Vogelzang, MD, FASCO, FACP, elaborates on combining checkpoint inhibitors in mCRPC

video-image

Michael Atkins, MD, regarding single agent TKIs in the 1st line setting

video-image

Nicholas Vogelzang, MD, FASCO, FACP, regarding combination pembrolizumab and olaparib in mCRPC

video-image

Nicholas Vogelzang, MD, FASCO, FACP, offers his impression of KEYNOTE 365 in mCRPC

video-image

Nicholas Vogelzang, MD, FASCO, FACP, regarding the evolution of ADT in prostate cancer

video-image

Nicholas Vogelzang, MD, FASCO, FACP, on the evolving treatment landscape of nmCRPC

video-image

Evan Yu, MD, considers when sipuleucel-T should be used in treatment of mCRPC

video-image

Evan Yu, MD, on combining checkpoint inhibitors in metastatic castration-resistant prostate cancer

video-image

Sumit K. Subudhi, MD, PhD, discusses combining checkpoint inhibitors in mCRPC

video-image

Evan Yu, MD, regarding combination pembrolizumab and olaparib in mCRPC

video-image

Sumit K. Subudhi, MD, PhD, on when sipuleucel-T should be used in treatment of mCRPC

video-image

Evan Yu, MD, elaborates on the results from KEYNOTE 365 in mCRPC

video-image

Bridget F. Koontz, MD, speculates on the evolving landscape of prostate cancer

video-image

Sumit K. Subudhi, MD, PhD, considers the outcomes of the KEYNOTE 365 study

video-image

Bridget F. Koontz, MD, regarding new guidelines on hypofractionated EBRT in prostate cancer

video-image

Tomasz Beer, MD, regarding the ARAMIS study in nmCRPC from GU 2019

video-image

Bridget F. Koontz, MD, on moderate hypofractionation & ultra-hypofractionation in prostate cancer

video-image

Tomasz Beer, MD, elaborates on recent data utilizing LuPSMA in men with mCRPC

video-image

William Oh, MD, discusses the evolving treatment landscape for patients with nmCRPC

video-image

William Oh, MD, tells us how PSA is valuable as a biomarker in the treatment of prostate cancer

video-image

William Oh, MD, discusses recent data examining LuPSMA in men with mCRPC

video-image

William Oh, MD, regarding data on racial differences in response to novel prostate cancer therapies

video-image

Yair Lotan, MD, considers the role of checkpoint inhibitors in bladder cancer

video-image

Yair Lotan, MD, shares outcomes of KEYNOTE 057 in high-risk non-muscle-invasive bladder cancer

video-image

Mark T. Fleming, MD, regarding the implications of the CHECKMATE 650 study presented at GU 2019

video-image

Yair Lotan, MD, on the challenges using biomarkers for treatment selection in bladder cancer

video-image

Mark T. Fleming, MD, regarding the Aramis study in prostate cancer

video-image

Yair Lotan, MD, on molecular characterization & subtyping data in bladder cancer

video-image

Mark T. Fleming, MD, offers his impression of the LATITUDE study in NDx-HR mCNPC

video-image

Yair Lotan, MD, considers the latest in screening for high-risk asymptomatic bladder cancer

video-image

Mark T. Fleming, MD, on the ARCHES trial in metastatic hormone-sensitive prostate cancer

video-image

Andrew Armstrong, MD, offers opinion on androgen receptor inhibitors

video-image

Andrew Armstrong, MD, discusses the Phase 2 STREAM study in pre-metastatic prostate cancer

video-image

Andrew Armstrong, MD, presents an overview of the ARCHES trial in mHSPC

video-image

Yair Lotan, MD, considers the implications of the POUT study presented at ASCO GU 2018

video-image

Yair Lotan, MD, explains how new guidelines have changed the treatment of bladder cancer

video-image

Yair Lotan, MD, regarding the role of molecular markers in high-risk bladder cancer patients

video-image

Yair Lotan, MD, on how multi-modality treatment is being applied to locally advanced bladder cancer

video-image

Petros Grivas, MD, PhD, on the role of DNA repair gene mutations in metastatic urothelial carcinoma

video-image

Petros Grivas, MD, PhD, outlines the POUT study presented at ASCO GU 2018

video-image

Petros Grivas, MD, PhD, discusses molecular characterization & bladder subtyping data

video-image

Petros Grivas, MD, PhD, considers the role of the PD-L1 biomarker in the treatment of bladder cancer

video-image

Petros Grivas, MD, PhD, on combining immunotherapy and chemotherapy in metastatic bladder cancer

video-image

Petros Grivas, MD, PhD, regarding the role of immunotherapy in metastatic bladder cancer

video-image

Daniel P. Petrylak, MD, on the role of DNA repair gene mutations in metastatic urothelial carcinoma

video-image

Daniel P. Petrylak, MD, offers opinion on the POUT study presented at ASCO GU 2018

video-image

Daniel P. Petrylak, MD, on molecular characterization & bladder subtyping in bladder cancer

video-image

Daniel P. Petrylak, MD, on immunotherapy & chemotherapy combinations in metastatic bladder cancer

video-image

Daniel J. George, MD, discusses the difference in mortality in the PROSPER and SPARTAN trials

video-image

Daniel J. George, MD, regarding the conclusions from the SPARTAN study at ASCO GU 2018

video-image

Peter C. Black, MD, FACS, FRCSC, outlines the results of the POUT study presented at ASCO GU 2018

video-image

Peter C. Black, MD, FACS, FRCSC, on molecular characterization & bladder subtyping data

video-image

Peter C. Black, MD, FACS, FRCSC, regarding checkpoint blockade in non-muscle invasive bladder cancer

video-image

Nicholas J. Vogelzang, MD, on the benefit of adding docetaxel to 1st line, long-term hormone therapy

video-image

Nicholas J. Vogelzang, MD, discusses the difference in mortality in the PROSPER and SPARTAN trials

video-image

Nicholas J. Vogelzang, MD, regarding the conclusions from the SPARTAN trial at ASCO GU 2018

video-image

Nicholas J. Vogelzang, MD, outlines the results of the PROSPER study presented at ASCO GU 2018

video-image

Thomas Powles, MD, MBBS, MRCP, regarding immunotherapy & chemotherapy combinations in bladder cancer

video-image

William K. Oh, MD, on abiraterone acetate fine particle formulation

video-image

William K. Oh, MD, discusses how PET scans are changing the way we diagnose & treat prostate cancer

video-image

William K. Oh, MD, considers the impact of apalutamide on M0 CRPC patients

video-image

Christopher J. Kane MD, FACS, considers how radiotherapy should be applied after prostatectomy

video-image

Christopher J. Kane MD, FACS, regarding the use of neoadjuvant therapy in prostate cancer

video-image

Christopher J. Kane MD, FACS, on how the field of imaging is evolving

video-image

Maha Hussain, MD, FACP, FASCO, offers opinion on how to avoid over-treatment and under-treatment

video-image

Maha Hussain, MD, FACP, FASCO, considers the integration of biomarkers into treatment algorithms

video-image

Maha Hussain, MD, FACP, FASCO, regarding immunotherapy & castrate-resistant prostate cancer

video-image

Peter C. Black, MD, FACS, FRCSC, on impact of The Cancer Genome Atlas Project in bladder cancer

video-image

Mark Emberton, MD, on how we avoid under diagnosing and over diagnosing in prostate cancer

video-image

Daniel P. Petrylak, MD, regarding PD-L1 biomarkers in the treatment of bladder cancer

video-image

Daniel P. Petrylak, MD, outlines overall survival and immune responses from the STRIDE study

video-image

Daniel P. Petrylak, MD, on the Phase I data of enfortumab vedotin in mUC patients from ASCO GU 2018

video-image

Daniel J. George, MD, tells us about the results of the PROSPER study presented at ASCO GU 2018

video-image

Daniel J. George, MD, on how genomics are being incorporated into prostate cancer treatment

video-image

Peter C. Black, MD, FACS, FRCSC, considers preferred checkpoint inhibitors for urothelial carcinoma

video-image

Peter C. Black, MD, FACS, FRCSC, on the usefulness of molecular markers in bladder cancer treatment

video-image

Nicholas J. Vogelzang, MD, considers genomics and systemic therapy in advanced prostate cancer

video-image

Nicholas J. Vogelzang, MD, regarding the latest trends in diagnosis of advanced prostate cancer

video-image

Nicholas J. Vogelzang, MD, on immunotherapy & prostate cancer treatment algorithms

video-image

Thomas Powles, MD, MBBS, MRCP, on the evolving landscape of metastatic bladder cancer

video-image

Thomas Powles, MD, MBBS, MRCP, considers molecular markers and muscle-invasive bladder cancer

video-image

William K. Oh, MD, on biomarkers and prostate cancer treatment algorithms

video-image

William K. Oh, MD, regarding the results of the PROSPER and SPARTAN studies at ASCO GU 2018

video-image

Christopher J. Kane MD, FACS, considers how MRI is helping diagnose and treat prostate cancer

video-image

Christopher J. Kane MD, FACS, on trends in the multimodality treatment of localized prostate cancer

video-image

Maha Hussain, MD, FACP, FASCO, on the potential impact of the PROSPER study

video-image

Maha Hussain, MD, FACP, FASCO, discusses the results of the PROSPER study at ASCO GU 2018

video-image

Mark Emberton, MD, on imaging as an effective tool for diagnosing prostate cancer

video-image

Mark Emberton, MD, elaborates on the acceptance of imaging as a diagnostic tool in prostate cancer

video-image

Mark Emberton, MD, describes how MRI has improved the diagnosis of prostate cancer

video-image

Mark Emberton, MD, offers opinion on new ways to screen for prostate cancer

video-image

Mark Emberton, MD, regarding the evolution of imaging in localized prostate cancer

video-image

Mark Emberton, MD, considers the challenges in diagnosing men with prostate cancer

video-image

Ana Aparicio, MD, explains data and conclusions from her presentation at ASCO GU 2017

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on treating metastatic prostate cancer with multiple drugs

video-image

Robert B. Den, MD, give his thoughts on the most intriguing research presented at ASCO GU

video-image

Jeffrey M. Holzbeierlein, MD, highlights the most promising data coming out of ASCO GU 2017

video-image

Neal D. Shore, MD, FACS, provides insight into data on resistance and advanced prostate cancer

video-image

Ana Aparicio, MD, on how to sequence commonly used agents in metastatic prostate cancer

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, discusses resistance and advanced prostate cancer

video-image

Robert B. Den, MD, discusses the recent changes in radiation treatment for invasive bladder cancer

video-image

David J. McConkey, PhD, on which drugs have the highest potential to impact bladder cancer treatment

video-image

Jeffrey M. Holzbeierlein, MD, offers his opinion on interesting presentations from ASCO GU 2017

video-image

Neal D. Shore, MD, FACS, explains the impact of CHAARTED and STAMPEDE

video-image

Matthew I. Milowsky, MD, outlines treating bladder cancer with checkpoint inhibitors

video-image

Ana Aparicio, MD, on immunotherapy as a future treatment guideline for metastatic prostate cancer

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on immunotherapy and metastatic prostate cancer

video-image

Freddie C. Hamdy, MD, offers his opinion on exciting research from ASCO GU 2017

video-image

David J. McConkey, PhD, on treating bladder cancer with checkpoint inhibitors

video-image

Jeffrey M. Holzbeierlein, MD, gives his perspective on treatment trends in urology for 2017

video-image

Neal D. Shore, MD, FACS, on where chemotherapy fits into prostate cancer treatment

video-image

Alexandra Drakaki, MD, PhD, shares highlights from sessions in bladder cancer at ASCO GU 2017

video-image

Matthew I. Milowsky, MD, explains how genomics are changing the way we treat bladder cancer subtypes

video-image

Aly-Khan Lalani, MD, shares the results of his ASCO GU 2017 poster session

video-image

Ana Aparicio, MD, on commercial AR-V7 tests and metastatic castrate-resistant prostate cancer

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, explains the influence of CHAARTED and STAMPEDE

video-image

Robert B. Den, MD, on which patients with low-risk prostate cancer should receive radiation

video-image

Freddie C. Hamdy, MD, on putting into practice what we’ve learned from the ProtecT study

video-image

David J. McConkey, PhD, provides information on treating bladder cancer with checkpoint inhibitors

video-image

Mohamad E. Allaf, MD, shares the most intriguing research presented at ASCO GU 2017

video-image

Ana Aparicio, MD, discusses where chemotherapy fits in regard to prostate cancer treatment

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on BRCA1 and BRCA2 genetic testing as guidelines

video-image

Robert B. Den, MD, on the QOL differences between clinically localized prostate cancer patients

video-image

Freddie C. Hamdy, MD, elaborates on factors from the ProtecT study

video-image

David J. McConkey, PhD, on non-invasive imaging and monitoring metastatic bladder cancer

video-image

Jeffrey M. Holzbeierlein, MD, on the impact of his data presented at ASCO GU 2017

video-image

Neal D. Shore, MD, FACS, on metastatic castration-resistant prostate cancer patients

video-image

Alexandra Drakaki, MD, PhD, on what we need to know about checkpoint inhibitors and bladder cancer

video-image

Matthew I. Milowsky, MD, on the role of genomics in understanding heterogeneity in bladder cancer

video-image

Ana Aparicio, MD, discusses the impact of CHAARTED and STAMPEDE on her treatment decisions

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on metastatic castration-resistant prostate cancer patients

video-image

Robert B. Den, MD, on the recent adoption of radiation treatment for advanced prostate cancer

video-image

Freddie C. Hamdy, MD, informs us on the ProtecT study top line results

video-image

David J. McConkey, PhD, on the responses to immunotherapy for varied bladder cancer subtypes

video-image

David J. McConkey, PhD, on the influence of genomics for the treatment of bladder cancer subtypes

video-image

Ulka N. Vaishampayan, MD, provides her opinion on the most interesting research at ASCO GU 2017

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, discusses the influence of an AR-V7 commercial test

video-image

Neal D. Shore, MD, FACS, on the impact of an AR-V7 commercial test

video-image

Jeffrey M. Holzbeierlein, MD, summarizes data and conclusions from his presentation at ASCO GU 2017

video-image

Neal D. Shore, MD, FACS, on BRCA1 and BRCA2 genetic testing as guidelines for prostate cancer

video-image

Alexandra Drakaki, MD, PhD, describes her work with microRNA and the potential clinical implications

video-image

Matthew I. Milowsky, MD, shares highlights from his lecture on urothelial carcinoma

video-image

Aly-Khan Lalani, MD, provides feedback on which ASCO GU research presentations were most intriguing

video-image

Ana Aparicio, MD, on metastatic castration-resistant prostate cancer patients and chemotherapy

video-image

Robert B. Den, MD, considers topics in the “Best of Journals: Prostate Cancer” panel discussion

video-image

Freddie C. Hamdy, MD, on how the design of the ProtecT study works

video-image

David J. McConkey, PhD, discusses how genomics helps us understand heterogeneity in bladder cancer

video-image

Nicholas J. Vogelzang, MD, on where chemotherapy fits into treatment for prostate cancer

video-image

Evaluation of response to enzalutamide consecutively after disease progression on abiraterone prednisone

video-image

Recommendations for the utilization of molecular factors in treatment planning for localized prostate cancer ASCO GU 2016

video-image

Using new therapies earlier in prostate cancer may returns better results

video-image

Avelumab tolerable for patients according to JAVELIN Solid Tumor phase Ib trial

video-image

Potential role for combinations of CYP17 inhibitors and AR inhibitors in Castration Resistant Prostate Cancer

video-image

Choosing predictive markers for PD-1 and PD-L1 inhibitors in RCC - Dr. Walter Stadler